Biocon Share Price in Focus; Reports 15% Revenue Rise in Q1 FY26 Results

Biocon Limited announced its consolidated financial results for the quarter ended June 30, 2025.

Biocon Q1 FY26 Results

Consolidated revenue stood at ₹4,022 crore, marking a 15% year-on-year (YoY) increase on a like-for-like basis. Operating revenue reached ₹3,942 crore, also up 15% after adjusting for the one-time Biocon Fine Chemicals (BFI) divestment gain recorded in Q1 FY25.

EBITDA for the quarter was ₹829 crore, representing a 19% YoY rise, with an EBITDA margin of 21%. Core EBITDA grew 11% to ₹1,003 crore, maintaining a robust core margin of 25%. Profit Before Tax (PBT) before exceptional items surged 72% YoY to ₹97 crore, while net profit before exceptional items stood at ₹31 crore, a significant 342% jump on a like-for-like basis. Reported net profit also stood at ₹31 crore, reflecting a 65% increase.

Research & Development Investments

Net R&D investments amounted to ₹205 crore during the quarter, accounting for 7% of revenue (excluding Syngene). This continued commitment to R&D underscores Biocon’s focus on pipeline expansion and innovation in its core therapeutic areas.

Segment-Wise Performance

• Generics (APIs & Generic Formulations): Revenue came in at ₹697 crore, registering a 6% YoY growth.
• Biosimilars (Biocon Biologics): The segment delivered strong momentum, with revenues rising 18% YoY to ₹2,458 crore, driven by increased market penetration and product launches.
• CRDMO & Research Services (Syngene): Posted revenues of ₹875 crore, marking an 11% YoY increase, reflecting steady growth in contract research and manufacturing demand.

Strategic Outlook

The company’s performance reflects continued growth momentum in its biosimilars business and resilience in generics despite competitive pressures. The strong uptick in PBT and profitability is aided by operational efficiencies and an improved business mix.

Biocon Share Price Performance

On August 8, 2025, Biocon share price opened at ₹358.95, down from its previous close of ₹364.20. At 10:22 AM, the share price of Biocon was trading at ₹358.55, down by 1.55% on the NSE.

Also Read: Biocon Recieves USFDA Approval for 'Kristy'!

Conclusion

Biocon’s Q1 FY26 results highlight robust top-line growth, margin stability, and significant improvement in profitability, particularly on a like-for-like basis. With sustained R&D investments and strong biosimilars performance, Biocon is well-positioned to strengthen its global presence and drive long-term value creation.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.